146 related articles for article (PubMed ID: 1729424)
1. Cardiovascular implications of anabolic steroid abuse.
Cheever K; House MA
J Cardiovasc Nurs; 1992 Jan; 6(2):19-30. PubMed ID: 1729424
[TBL] [Abstract][Full Text] [Related]
2. Testosterone, sex hormone-binding globulin, lipoproteins, and vascular disease risk.
Dickerman RD; McConathy WJ; Zachariah NY
J Cardiovasc Risk; 1997; 4(5-6):363-6. PubMed ID: 9865668
[TBL] [Abstract][Full Text] [Related]
3. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids.
Lane HA; Grace F; Smith JC; Morris K; Cockcroft J; Scanlon MF; Davies JS
Eur J Clin Invest; 2006 Jul; 36(7):483-8. PubMed ID: 16796605
[TBL] [Abstract][Full Text] [Related]
4. Anabolic steroid abuse: physiological and anaesthetic considerations.
Kam PC; Yarrow M
Anaesthesia; 2005 Jul; 60(7):685-92. PubMed ID: 15960720
[TBL] [Abstract][Full Text] [Related]
5. [Cardiovascular side effects of anabolic-androgenic steroids].
Kindermann W
Herz; 2006 Sep; 31(6):566-73. PubMed ID: 17036188
[TBL] [Abstract][Full Text] [Related]
6. Abuse of anabolic androgenic steroids and related substances in sport and exercise.
Bahrke MS; Yesalis CE
Curr Opin Pharmacol; 2004 Dec; 4(6):614-20. PubMed ID: 15525553
[TBL] [Abstract][Full Text] [Related]
7. [Endocrine effects of doping with androgenic anabolic steroids].
Birkeland KI; Jørgensen J; Hemmersbach P
Tidsskr Nor Laegeforen; 1994 Feb; 114(4):426-8. PubMed ID: 8009475
[TBL] [Abstract][Full Text] [Related]
8. [Anabolic steroids and their abuse in sports].
Bruno M
Clin Ter; 1990 Nov; 135(3):159-72. PubMed ID: 2150017
[TBL] [Abstract][Full Text] [Related]
9. Androgenic-anabolic steroids abuse in males.
Di Luigi L; Romanelli F; Lenzi A
J Endocrinol Invest; 2005; 28(3 Suppl):81-4. PubMed ID: 16042364
[TBL] [Abstract][Full Text] [Related]
10. Adverse cardiovascular effects from the use of anabolic-androgenic steroids as ergogenic resources.
Santos MA; Oliveira CV; Silva AS
Subst Use Misuse; 2014 Jul; 49(9):1132-7. PubMed ID: 24832723
[TBL] [Abstract][Full Text] [Related]
11. Adverse cardiovascular effects of anabolic steroids: pathophysiology imaging.
Golestani R; Slart RH; Dullaart RP; Glaudemans AW; Zeebregts CJ; Boersma HH; Tio RA; Dierckx RA
Eur J Clin Invest; 2012 Jul; 42(7):795-803. PubMed ID: 22299602
[TBL] [Abstract][Full Text] [Related]
12. Use of steroids for self-enhancement: an epidemiologic/societal perspective.
Yesalis CE
AIDS Read; 2001 Mar; 11(3):157-60. PubMed ID: 17004353
[TBL] [Abstract][Full Text] [Related]
13. Effect of androgenic and anabolic steroids on the sebaceous gland in power athletes.
Király CL; Alén M; Rahkila P; Horsmanheimo M
Acta Derm Venereol; 1987; 67(1):36-40. PubMed ID: 2436412
[TBL] [Abstract][Full Text] [Related]
14. Androgenic anabolic steroid abuse and the cardiovascular system.
Vanberg P; Atar D
Handb Exp Pharmacol; 2010; (195):411-57. PubMed ID: 20020375
[TBL] [Abstract][Full Text] [Related]
15. Anabolic-androgenic steroid abuse and performance-enhancing drugs among adolescents.
Bahrke MS; Yesalis CE; Brower KJ
Child Adolesc Psychiatr Clin N Am; 1998 Oct; 7(4):821-38. PubMed ID: 9894044
[TBL] [Abstract][Full Text] [Related]
16. ESC study group of sports cardiology position paper on adverse cardiovascular effects of doping in athletes.
Deligiannis A; Björnstad H; Carre F; Heidbüchel H; Kouidi E; Panhuyzen-Goedkoop NM; Pigozzi F; Schänzer W; Vanhees L;
Eur J Cardiovasc Prev Rehabil; 2006 Oct; 13(5):687-94. PubMed ID: 17001206
[TBL] [Abstract][Full Text] [Related]
17. Anabolic androgenic steroids and forebrain GABAergic transmission.
Henderson LP; Penatti CA; Jones BL; Yang P; Clark AS
Neuroscience; 2006; 138(3):793-9. PubMed ID: 16310317
[TBL] [Abstract][Full Text] [Related]
18. Anabolic steroids: what should the emergency physician know?
Brown JT
Emerg Med Clin North Am; 2005 Aug; 23(3):815-26, ix-x. PubMed ID: 15982547
[TBL] [Abstract][Full Text] [Related]
19. [Use of testosterone and anabolic androgenic steroids in sport].
Medraś M; Jóźków P
Endokrynol Pol; 2009; 60(3):204-9. PubMed ID: 19569021
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a decrease in cardiovascular risk factors following recombinant growth hormone administration in abstinent anabolic-androgenic steroid users.
Graham MR; Baker JS; Evans P; Kicman A; Cowan D; Hullin D; Davies B
Growth Horm IGF Res; 2007 Jun; 17(3):201-9. PubMed ID: 17324600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
